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A rare genetic variant of BPIFB4 
predisposes to high blood pressure 
via impairment of nitric oxide 
signaling
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Antonio Damato1, Mariateresa Ambrosio1, Anna Ferrario4, Michele Madonna1, Annachiara 
Uccellatore5, Silvia Lupini5, Anna Maciag3, Larisa Ryskalin  6, Luciano Milanesi  4, Giacomo 
Frati1,7, Sebastiano Sciarretta1,7, Riccardo Bellazzi8,9, Stefano Genovese10, Antonio Ceriello10, 
Alberto Auricchio11,12, Alberto Malovini8 & Annibale Alessandro Puca2,3
BPIFB4 is associated with exceptional longevity: four single-nucleotide polymorphisms distinguish 
the wild-type form from a longevity-associated variant conferring positive effects on blood pressure. 
The effect of a rare variant (RV; allele frequency, 4%) on blood pressure is unknown. Here, we show 
that overexpression of RV-BPIFB4 in ex-vivo mouse vessels impairs phosphorylation of endothelial 
nitric oxide synthase (eNOS), blunting acetylcholine-evoked vasorelaxation; in vivo, virally mediated 
overexpression of RV-BPIFB4 increases blood pressure, an action absent in eNOS-deficient mice. In 
humans, we found RV carriers to have increased diastolic blood pressure, a finding that was more 
marked in subjects on anti-hypertensive medication; moreover, recombinant RV-BPIFB4 protein 
impaired eNOS function in ex-vivo human vessels. Thus, RV-BPIFB4 acts directly on blood pressure 
homeostasis and may represent a novel biomarker of vascular dysfunction and hypertension.
There is tight correlation between exceptional longevity and integrity of the cardiovascular system. An example is 
the fine-tuning of blood pressure: this is lost during aging, becoming a strong risk factor for disability and mor-
tality. Indeed, reduced activity during aging of endothelial nitric oxide synthase (eNOS) – a crucial enzyme for 
endothelial integrity and function – leads to increased susceptibility to cardio- and cerebro-vascular diseases1–4. 
The importance of eNOS is underscored by the fact that caloric restriction – which protects the cardiovascular 
system and extends life-span – is inefficient in a context of eNOS gene knock-down5.
Long-living individuals (LLIs) carry a favorable genetic profile characterized by an enrichment of alleles 
that protect from aging-related and cardiovascular diseases6, 7. One of these alleles is the minor allele rs2070325 
(I229V) of bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4), which we found 
enriched as a homozygous trait in LLIs8. rs2070325 is part of a four-SNP (single-nucleotide polymorphism) hap-
lotype that distinguishes the wild-type (WT) Ile229/Asn281/Leu488/Ile494-BPIFB4 isoform (allele frequency, 
66%) from the longevity-associated variant (LAV) Val229/Thr281/Phe488/Thr494-BPIFB4 (allele frequency, 
29.5%); a rare variant (RV) Ile229/Asn281/Phe488/Thr494-BPIFB4 – which retains only the third and fourth 
amino acid substitutions of the LAV– is also present (allele frequency, 4%).
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Homozygous (a/a) rs2070325 individuals have significantly more eNOS activated in their mononuclear cells 
than do heterozygous (a/A) or WT (A/A) carriers8, and healthily aged LLIs have significantly higher serum 
BPIFB4 than do frail individuals9. In a murine model of mesenteric artery function – involving adeno-associated 
virus 9-mediated overexpression of a BPIFB4 isoform in vivo and subsequent assessment of vascular functionality 
ex vivo – the LAV potentiated eNOS activity and endothelial function, reducing blood pressure levels; no effect 
was observed with WT-BPIFB4. Furthermore, overexpression of LAV-BPIFB4 improved stem-cell homing and 
revascularization in a model of limb ischemia. Compared to WT-BPIFB4, the LAV was more cytoplasmic, more 
phosphorylated at serine 75 by the protein kinase R–like endoplasmic reticulum kinase (PERK), and was more 
efficiently bound to protein 14-3-3, forming a complex needed for the recruitment of heat shock protein (HSP)90 
and eNOS activation8. In that study, the effect of the RV was not determined.
Here, we show that overexpression of the RV in WT mice impairs eNOS signaling and endothelial function, 
evoking an increase in blood pressure. Coherently, no effects were observed in eNOS-deficient mice. Of note, 
we found in humans that RV-BPIFB4 carriers had significantly increased blood pressure. Moreover, exposure of 
ex-vivo human vessels to a recombinant RV-BPIFB4 protein negatively modulated endothelial function and eNOS 
activation, corroborating the findings in mice.
Results
Overexpression of RV-BPIFB4 in ex-vivo mouse vessels impairs endothelial function and eNOS 
activation. We first explored whether the RV modulated vascular tone in an experimental model. To this end, 
we transfected ex-vivo mouse mesenteric arteries with plasmids encoding either RV-BPIFB4 or the WT isoform. 
Overexpression of RV-BPIFB4 impaired acetylcholine-evoked vasorelaxation (Fig. 1A–D) and eNOS phospho-
rylation at serine 1177 (Fig. 1E), the main activation site of the enzyme. Moreover, phosphorylation of BPIFB4 at 
serine 75 – which is needed to recruit 14-3-3 and activate eNOS-dependent production of NO – was significantly 
reduced by overexpression of RV-BPIFB4 (Fig. 1E).
Administration of AAV-RV-BPIFB4 increases blood pressure in mice. To evaluate the in-vivo rel-
evance of the findings obtained through plasmid transfection, we generated RV- and WT-BPIFB4-encoding 
adeno-associated viral vectors (AAV; serotype 9 with a TBG promoter), and administered them to normotensive 
mice through the femoral artery. Compared to control, AAV-RV-BPIFB4 significantly increased systolic blood 
pressure (SBP) two days after infection; SBP reached a maximum at day 3 and returned to a level that was not sig-
nificantly different from baseline at day 4 (Fig. 2A). AAV-WT-BPIFB4 did not elicit any effect on blood pressure, 
as reported previously by us8.
Analyses of the mesenteric arteries harvested after blood pressure measurements showed that phosphoryla-
tion on eNOS and BPIFB4 was impaired in vessels of mice administered AAV-RV-BPIFB4 (Fig. 2B); coherently 
with what we observed with ex-vitro plasmid transfections, acetylcholine-elicited endothelial vasorelaxation was 
blunted in these vessels, whereas that elicited by nitroglycerine was not (Fig. 2C,D).
To definitively define the role of NO in the negative effect of RV-BPIFB4 on vascular homeostasis, we per-
formed experiments on eNOS-deficient mice, which present with higher blood pressure levels when compared 
to WT counterparts. In this experimental setting, transduction with AAV-RV-BPIFB4 failed to influence SBP 
(Fig. 2E). Of note, the SBP of WT mice transduced with AAV-RV-BPIFB4 rose to a level that was not signifi-
cantly different to the baseline in eNOS-deficient mice. At the functional level, ex-vivo vascular reactivity studies 
showed that infection with AAV-RV-BPIFB4 impaired acetylcholine-evoked vasorelaxation in WT vessels to a 
similar extent to that inherent in eNOS-deficient ones (Fig. 2F). These data clearly demonstrate that impairment 
of NO is responsible for the negative effect of RV-BPIFB4 on vascular function and blood pressure.
RV-BPIFB4 is associated with high blood pressure in humans. In the Pilot 1 data set of the 1000 
Genomes Project–Coriell Institute for Medical Research (http://www.1000genomes.org/category/phase-1/), 
the rs2070325 (Ile229Val) variation of BPIFB4 (identifier: P59827.2) is strongly correlated with rs2889732 
(Asn281Thr) (r2 = 0.93; D′ = 1); both variations show a limited amount of recombination events with rs11699009 
(Leu488Phe) and rs11696307 (Ile494Thr) (r2 > 0.85; D′ > 0.92). Therefore, the three main alternative haplotypes 
of BPIFB4 are the WT (Ile229/Asn281/Leu488/Ile494-BPIFB4), LAV (Val229/Thr281/Phe488/Thr494-BPIFB4), 
and RV (Ile229/Asn281/Phe488/Thr494-BPIFB4) isoforms, which carry the major alleles rs2070325 (A) and 
rs2889732 (A) and the minor alleles rs11699009 (T) and rs11696307 (C). Thus, we genotyped for rs2070325 and 
rs11699009 to determine the haplotype of 461 consecutive individuals that had been enrolled for an epidemiology 
study on diabetes. The clinical characteristics of the cohort are reported in Table 1. Supplementary Table 1 gives 
the association of the considered clinical variables with diastolic and systolic blood pressures.
The two tested SNPs (rs2070325 and rs11699009) were characterized by intermediate to strong evidence of 
linkage disequilibrium (r2 = 0.80; D′ = 0.96); neither deviated significantly from the Hardy–Weinberg equilib-
rium (HWE, p > 0.05), with missing data fractions corresponding to 4% and 6%, respectively. The allele frequen-
cies of the analyzed variants and deriving haplotype alleles are reported in Table 2. A total number of 418 subjects 
(91%) had no missing values for the two SNPs and for SBP and DBP measurements.
The association of both SNPs with DBP and SBP traits was tested assuming a recessive model (rs2070325: 
GG vs. GA/AA; and rs11699009: TT vs. TC/CC). Since the LAV is represented by the minor allele of the two 
SNPs in haplotypic phase, a recessive model was tested for this allele too (i.e., LAV homozygotes – defined as 
rs2070325 = G and rs11699009 = T on both chromosomes – vs. LAV heterozygotes – defined as rs2070325 = G 
and rs11699009 = T on one chromosome – plus remaining haplotype carriers pooled). For the remaining two 
haplotypes with frequency >1% (i.e., RV and WT), dominant and recessive genetic models were assumed (i.e., 
for RV, RV haplotype carriers – defined as rs2070325 = A and rs11699009 = T on at least one chromosome – 
vs. non-carriers; and for WT, WT homozygotes – defined as rs2070325 = A and rs11699009 = C on both 
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chromosomes – vs. WT heterozygotes – defined as rs2070325 = A and rs11699009 = C on one chromosome – 
plus remaining haplotype alleles pooled, respectively). Of note, less than 1% of patients were heterozygous car-
riers for rs2070325 and WT at rs11699009, so we can assume that all individuals heterozygous for both SNPs are 
bona fide heterozygous carriers of the LAV because the chance of finding a compound heterozygous for rs2070325 
and rs1699009 is <1/1,000.
Of the two tested variants, individuals homozygote for the minor allele rs2070325 shared a statistically sig-
nificant reduction in terms of DBP when compared to major allele carriers (Table 3). No statistically significant 
impact of the SNP was observed on SBP (Table 4). Similarly, individuals homozygote for the LAV haplotype had 
a statistically significant reduction in terms of DBP when compared to the rest of the cohort. No association 
between the LAV and SBP was observed.
Figure 1. Response of ex vivo mouse mesenteric arteries to transfection with RV-BPIFB4. (A,B) Graphs 
of vascular response to increasing doses of acetylcholine (ACh) or nitroglycerine in mouse mesenteric 
arteries before and after transfection with plasmids encoding WT-BPIFB4. (C,D) Graphs of vascular 
response to increasing doses of acetylcholine (ACh) or nitroglycerine in mouse mesenteric arteries 
before and after transfection with plasmids encoding RV-BPIFB4 (n = 7 for each experiment). *p < 0.05; 
**p < 0.01;***p < 0.001 (two-way ANOVA followed by Bonferroni post hoc test). (E) left, Representative 
immunoblot of mesenteric artery lysate collected after vascular reactivity studies; right, Optical density 
measurements of immunoblottings. Columns are the mean ± SEM of 3 independent experiments. *p < 0.05 
(one-way ANOVA analysis followed by Bonferroni post hoc test). Images were cropped using Adobe 
Photoshop, full-length blots are presented in Supplementary Fig. 2.
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RV carriers were characterized by significantly increased DBP and by a borderline increase in SBP (Tables 3 
and 4). Stepwise linear regression, with a combination of forward search and backward elimination, starting 
from the full set of informative demographical and clinical covariates (see Methods section), confirmed that the 
Figure 2. In vivo infection of mice with RV-BPIFB4. (A) Graph of systolic blood pressure (SBP) in C57BL/6 
mice infected with AAV vectors encoding WT-BPIFB4, RV-BPIFB4, or green fluorescent protein (GFP). The 
arrow indicates injection of AAV in the femoral artery (day 0). Data are mean ± SEM (n = 6/group). *p < 0.05; 
**p < 0.01 vs. AVV-WT-BPIFB4; ##p < 0.01 vs. AVV-GFP (two-way ANOVA followed by Bonferroni post hoc 
test). (B) representative immunoblottings (left) and optical density measurements (right) of mesenteric arteries 
harvested from infected mice. Columns are the mean ± SD of 3 independent experiments.*p < 0.05 (one-way 
ANOVA analysis followed by Bonferroni post hoc test). Images were cropped using Adobe Photoshop, full-
length blots are presented in Supplementary Fig. 3. (C,D) ex-vivo response of mesenteric arteries removed from 
mice after infection with AAV-WT-BPIFB4, AAV-RV-BPIFB4, or AAV-GFP to increasing doses of acetylcholine 
(ACh) or nitroglycerine. Two-way ANOVA, in combination with Bonferroni post-tests. (E) Graph of systolic 
blood pressure (SBP) in eNOS knock-out mice (eNOS−/−) and wild-type mice (eNOS+/+) infected with AAV 
vectors encoding RV-BPIFB4 or green fluorescent protein (GFP). The arrow indicates injection of AAV in the 
femoral artery (day 0). Data are mean ± SEM (n = 5/group). *p < 0.05; **p < 0.01 vs. AVV-GFP + eNOS+/+ 
(two-way ANOVA followed by Bonferroni post hoc test). (F) Graph of ex-vivo vascular response in mouse 
mesenteric arteries removed from wild-type C57BL/6 (eNOS+/+) and eNOS knock-out (eNOS−/−) mice 
infected with AAV-RV-BPIFB4 or AAV-GFP, to increasing doses of acetylcholine (ACh). Data are presented as 
mean ± SEM. *p < 0.05; **p < 0.01 vs. all (two-way ANOVA followed by Bonferroni post hoc test).
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RV modulated DBP even when accounting for potential confounders (Beta, 4.98 mm Hg; 95% CI, 1.15–8.81; 
p = 0.011) (Supplementary Table 2). Stepwise linear regression including the RV x anti-hypertensive treatment 
interaction term revealed a specific, increasing impact of the haplotype on DBP (interaction, p = 0.006) and 
on SBP (interaction, p = 0.007) in individuals under treatment, accounting for informative demographical and 
clinical covariates. Further analysis of the subgroup of patients taking medication for hypertension (n = 166) 
also showed that the presence of the rare haplotype variant had an increased effect in this subset (Tables 3 and 4). 
Multivariate stepwise linear regression including informative covariates confirmed the impact of the RV on DBP 
and SBP in this subgroup of individuals (DBP: Beta, 11.54 mm Hg; 95% CI, 52–17.56; p = 0.0002. SBP: Beta, 13.19 
mm Hg; 95% CI, 4.71–21.66; p = 0.003). No statistically significant differences in DBP or SBP were observed 
between RV carriers and non-carriers in the subgroup of 252 individuals not on anti-hypertensive medication. Of 
note, anti-hypertensive treatment did not differ in RV carriers vs. non-carriers, and did not significantly influence 
the association results (Supplementary Table 3).
We then compared the distribution of SBP and DBP in LAV homozygotes, RV carriers, and WT homozygotes 
within the whole cohort and within subgroups stratified on the basis of treatment (Supplementary Fig. 1). Mean 
DBP was significantly higher in the RV carrier group vs. the LAV homozygote and WT homozygote groups 
(p = 0.009 and p = 0.02, respectively), with more marked differences between the subgroups of patients taking 
anti-hypertensive drugs (p = 0.004 and p = 0.003, respectively). The RV carrier group was also characterized by 
a significantly increased mean SBP vs. the LAV homozygote group (p = 0.044), but not vs. the WT homozygote 
group (p = 0.074); again the differences were greater between subgroups on anti-hypertensive drugs (RV vs. LAV 
homozygotes, p = 0.002; and RV vs. WT homozygotes, p = 0.01).
Exposure to recombinant RV-BPIFB4 modulates the reactivity of human vessels. To assess 
whether the results obtained in the experimental models were relevant to the human setting, we performed 
Characteristic Value (n = 461)
Sex
 Male 194 (42.08%)
 Female 267 (57.92%)
Age (years) 62 (55–69); 61.18 ± 8.78
Diabetic status
 Non-diabetic 239 (51.96%)
 Pre-diabetic 164 (35.65%)
Diabetic 57 (12.39%)
Diastolic blood pressure 80 (70–85); 76.63 ± 11.93
Systolic blood pressure 130 (120–140); 128.69 ± 15.33
Glucose tolerance test (FPG) 89 (81–96); 86.69 ± 12.19
Glucose tolerance test (2HPG) 112.5 (91–138); 120.11 ± 42.45
Body mass index 26.40 (23.85–29.30); 27.01 ± 4.56
Triglyceridemia 99 (76–138); 115.85 ± 64.71
Total cholesterolemia 205.5 (180–229); 206.13 ± 35.68
High density lipoprotein 
cholesterolemia 56 (46–65); 56.84 ± 15.01
Anti-hypertensive treatment
 Yes 182 (60.52%)
 No 279 (39.48%)
Table 1. Clinical Characteristics of Enrolled Patients. Notes: FPG, fasting plasma glycemia; 2HPG, 2-hour 
plasma glycemia (after ingestion of 75 g glucose). Distributions are described by median (interquartile range); 
mean ± SD or frequency (%).
Variant Allele Frequency
rs2070325 A, G G (0.348), A (0.652)
rs11699009 C, T T (0.381), C (0.619)
Haplotype
 LAV rs2070325 = G; rs11699009 = T 0.337
 WT rs2070325 = A; rs11699009 = C 0.613
 RV rs2070325 = A; rs11699009 = T 0.042
 Other rs2070325 = G; rs11699009 = C 0.008
Table 2. SNPs and Haplotype Allele Frequencies1. 1Complete data on both SNPs, SBP, and DBP was obtained in 
418/461 subjects (91%).
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ex-vivo vascular reactivity studies on superior thyroid arteries removed from patients undergoing carotid 
revascularization. We chose vessels with the best endothelial vasodilation, evaluating the effects of RV- and 
WT-BPIFB4 recombinant proteins.
Exposure to recombinant RV-BPIFB4 protein significantly reduced acetylcholine-evoked endothelial vaso-
relaxation as compared to WT protein (Fig. 3A,B), an effect associated with impaired eNOS phosphorylation 
(Fig. 3C); no effect was observed on vasorelaxation evoked by nitroglycerine (data not shown).
Discussion
The complex interplay between genes and environmental factors affecting the regulation of blood pressure is not 
well understood yet. In this regard, cardiovascular medicine is increasingly focused on the search for new risk 
markers and potential therapeutic targets. Over the last few years, genome-wide association studies have iden-
tified more than 50 genetic variants associated with cardiovascular disease and have given valuable insights into 
the pathological mechanisms underlying specific disorders such as cerebrovascular and coronary artery diseases 
and myocardial infarction10, 11.
Genotype or haplotype allele
Set
Count
Median (IQR); Mean ± SD - SBP 
(mm Hg)
PRef. Baseline Ref. Baseline Ref. Baseline
SNP
 rs2070325 GG GA/AA All 46 394 70 (60–80); 73.59 ± 14.78
80 (70–85); 
76.99 ± 11.54 0.0259*
 rs11699009 TT TC/CC All 54 379 70 (60–90); 75.46 ± 14.99
80 (70–85); 
76.79 ± 11.53 0.2772
haplotype
 LAV LAV homo LAV carriers/other All 41 377 70 (60–80); 73.54 ± 14.76
80 (70–85); 
76.9 ± 11.67 0.0386*
 WT WT homo WT carriers/other All 149 269 80 (70–80); 76.17 ± 11.77
80 (70–85); 
76.8 ± 12.19 0.5652
 RV RV carriers other All 34 384 70 (76–90); 81.47 ± 12.22
80 (70–80); 
76.14 ± 11.93 0.0132*
On therapy 12 154 90 (80–100); 89.17 ± 9.25
80 (70–80); 
76.71 ± 11.27 0.0007*
No therapy 22 230 80 (70–88.75); 77.27 ± 11.72
80 (70–80); 
75.76 ± 12.37 0.5102
Table 3. Impact of SNPs and haplotypes on diastolic blood pressure. SNP/Haplotype = SNP or haplotype allele; 
Ref. = reference, effect genotype or haplotype allele; Baseline = baseline genotype or haplotype; set = subset 
of the cohort analyzed; Count = genotypes or alleles count; Median (IQR); Mean ± SD = median (25th, 75th 
percentiles) and mean ± standard deviation diastolic blood pressure by genotype or allele; p = p-value from the 
Wilcoxon rank sum test. *p-value < 0.05.
Genotype or haplotype allele
Set
Count
Median (IQR); Mean ± SD - SBP 
(mm Hg)
PRef. Baseline Ref. Baseline Ref. Baseline
SNP
rs2070325 GG GA/AA All 46 394 120 (110–140); 124.57 ± 15.73
130 (120–140); 
128.9 ± 15.20 0.0993
rs11699009 TT TC/CC All 54 379 130 (110–140); 126.76 ± 17.70
130 (120–140); 
128.94 ± 15.12 0.5825
haplotype
LAV LAV homo LAV carriers/other All 41 377 130 (110–140); 124.88 ± 15.83
130 (120–140); 
128.79 ± 15.30 0.1906
WT WT homo WT carriers/other All 149 269 130 (120–140); 127.89 ± 14.98
130 (120–140); 
128.69 ± 15.61 0.4990
RV RV carriers other All 34 384 130 (120–150); 133.38 ± 18.82
130 (120–140); 
127.96 ± 14.98 0.0670
On therapy 12 154 150 (137–150); 146.25 ± 15.54
130 (120–140); 
130.68 ± 15.67 0.0015*
No therapy 22 230 125 (120–138); 126.36 ± 16.85
130 (116–140); 
126.14 ± 14.25 0.9182
Table 4. Impact of SNPs and haplotypes on systolic blood pressure. SNP/Allele = SNP or haplotype allele; 
Ref. = reference, effect genotype or haplotype allele; Baseline = baseline genotype or haplotype; set = subset of 
the cohort analyzed; Count = genotypes or alleles count; Median (IQR); Mean ± SD = median (25th and 75th 
percentiles) and mean ± standard deviation systolic blood pressure by genotype or allele; p = p-value from the 
Wilcoxon rank sum test. *p-value < 0.05.
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Regarding hypertension, only 50% of patients attain good levels of blood pressure despite the wealth of 
pharmacological treatments available to them. Genetic studies are revealing how the genetic background 
of these patients influences the response to anti-hypertensive medication12. Indeed, the effect of a particular 
anti-hypertensive drug is influenced not only by the patient’s ethnicity but also by the disease’s genetic etiopathol-
ogy. Moreover, a complex hypertensive trait – and any correlated inefficacy of treatment – is generated in many 
cases by an interplay of genetic and environmental factors. There is also a growing body of evidence in favor of 
an inverse association between genetic factors of exceptional longevity and the risk of high blood pressure: for 
example, the expression of CAMK4 has been associated with exceptional longevity, whereas its deletion induces 
hypertension13, 14. Continuing along this line, the present study demonstrates that the expression of a rare variant 
of BPIFB4 – a protein we have previously associated with improved aging when present in its longevity-associated 
isoform – leads to the maintenance of high blood pressure in the face of treatment for hypertension. Many genes 
involved in the molecular mechanism of action of drugs have been reported to have polymorphisms that mod-
ulate drug efficacy: for example, the Arg389Gly substitution in the beta1-adrenergic receptor is associated with 
lower therapeutic efficacy of beta-blockers15–17.
Our findings on a small cohort of patients candidate RV-BPIFB4 as a possible genetic risk factor for high 
blood pressure. Thus, we focused our attention on experimental models in order to support the human study, 
which was performed on a limited number of subjects. First of all, we transfected mouse resistance vessels with 
plasmids encoding the RV or the WT isoform of BPIFB4 to evaluate the impact on vascular function, finding that 
RV-BPIFB4 impairs eNOS signaling and induces endothelial dysfunction, hallmarks of aging and cardiovascular 
disease. The detrimental effect of the RV on eNOS function was associated with impairment of phosphorylation 
on serine 75 of BPIFB4. This finding is coherent with our previous study demonstrating that phosphorylation of 
serine 75 on LAV-BPIFB4 has a protective effect on the cardiovascular system, enhancing eNOS function and 
NO release through recruitment of protein 14-3-3 and HSP908. We then injected RV- or WT-BPIFB4-encoding 
AAV vectors into mice, evaluating hemodynamic effects and vascular function: forced expression of RV-BPIFB4 
in WT mice evoked vascular eNOS dysfunction and increased basal systolic blood pressure to a degree similar to 
that seen in eNOS-deficient mice.
These studies on experimental models helped us understand the mechanisms underlying the influence of 
RV-BPIFB4 on cardiovascular homeostasis. To evaluate the significance of these findings for humans, we con-
structed a human recombinant RV-BPIFB4 protein and tested its effects on human vessels. The exposure of 
human vessels to this protein led to impairment of NO production and endothelial dysfunction, corroborating 
the results obtained in the mouse.
Figure 3. Reaction of ex vivo human arteries to exposure to recombinant WT- and RV-BPIFB4 proteins. 
(A,B) Dose-response of human superior thyroid arteries (STA) incubated for 1 hour with 18ng/mL of 
recombinant WT-BPIFB4 (A) or RV-BPIFB4 (B) protein to increasing doses of acetylcholine (Ach). Values are 
means ± SEM (n = 4 experiments).**p < 0.01 (two-way ANOVA followed by Bonferroni post hoc test). (C) left, 
Representative immunoblot of human STA after vascular reactivity studies; right, Columns are the mean ± SEM 
of 3 independent experiments. *p < 0.05 (Student’s t-test). Images were cropped using Adobe Photoshop, full-
length blots are presented in Supplementary Fig. 4.
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NO plays a key role in blood pressure homeostasis. Experimental models of hypertension strongly support 
this concept since impairment of NO production – either pharmacologically with L-NAME or genetically by 
inactivation of eNOS – increases blood pressure. RV-BPIFB4 hinders NO signaling, generating endothelial dys-
function and hypertension. It is not clear whether endothelial dysfunction – a typical trait of cardiovascular dis-
eases such as arterial hypertension – participates in hypertension or is evoked by high blood pressure. However, 
our in vivo experiments demonstrate that RV-BPIFB4 is involved in the impairment of eNOS function in a setting 
not influenced by high pressure, so endothelial dysfunction induced by the variant causes increased blood pres-
sure and not vice versa. Therefore, we can assert that RV-BPIFB4 is an important regulator of endothelial nitric 
oxide function and is a modulator of blood-pressure homeostasis.
Conclusions
BPIFB4 was recently identified among the genes contributing to equine evolution18. In the light of this, while 
LAV-BPIFB4 has been positively selected by evolution in man, RV-BPIFB4 could be the result of a stochastic 
recombination event that generated a WT/LAV-BPIFB4 chimera. Once confirmed in larger and well powered 
cohorts of subjects, the results of our study could suggest that the early identification of RV-BPIFB4 carriers could 
open new therapeutic perspectives for individuals who are predisposed to cardio- and cerebro-vascular diseases 
related to endothelial nitric oxide synthase dysfunction.
Study limitations. The present study’s design is not exposed to stratification bias typical of case-control stud-
ies. However, since post hoc simulations showed that our analyses reached sufficient statistical power to detect the 
effect sizes observed in the subset of individuals on therapy (>0.80) but not in the entire cohort (<0.80), studies 
conducted on larger groups of patients will be needed to better clarify whether RV-BPIFB4 can be regarded as 
an early marker of endothelial injury associated with hypertension. Large independent cohorts of individuals 
thoroughly characterized from a phenotypic point of view are therefore needed to confirm the association of this 
extremely rare haplotype (prevalence = 4%) with relevant variations in blood pressure. Further, the lack of statis-
tically significant differences in terms of BP between LAV and WT haplotypes could be due to the extremely low 
statistical power reached given the observed effect sizes and sample size (<0.25). Moreover, due to the multifacto-
rial characteristics of high blood pressure, the definition and validation of multivariate risk stratification schema, 
integrating genetic and clinical information, will allow early identification of patients at high risk of adverse events.
Methods
A supplemental section for more detailed methods is available online in the Supplementary Information file.
Ex vivo transfection of mouse vessels and evaluation of vascular reactivity. All experiments 
involving animals conformed with institutional guidelines and were approved by IRCCS INM Neuromed’s review 
board (1070/2015 PR) and complies with NIH guidelines for care and use of laboratory animals. Second-order 
branches of the mesenteric arterial tree were removed from C57BL/6 or eNOS-deficient (Nos3tm1Unc) mice and 
transfected as described previously19. Endothelium-dependent relaxation was assessed by measuring the dilatory 
responses of mesenteric arteries to cumulative concentrations of acetylcholine (from 10−9 M to 10−5 M) in ves-
sels pre-contracted with U46619 at a dose necessary to obtain a similar level of pre-contraction (80% of initial 
KCl-evoked contraction) in each ring20.
Infection of mice with AAV and measurements of vascular function and blood pressure. After 
temporary clamping of the proximal and distal femoral arteries of C57BL/6 or eNOS-deficient mice, either 100 µl 
of saline alone or saline plus AAV-WT-BPIFB4 or AAV-RV-BPIFB4 was infused. Mice were sacrificed four days 
after surgery and infection. Femoral arteries were excised and placed on a wire system for vascular reactivity 
studies. Systolic and diastolic blood pressures were measured in another experimental series of C57BL/6 mice by 
tail-cuff plethysmography, as previously described21.
Patient recruitment. The study was performed on a population of 461 individuals. For each, venous blood 
(10 mL) was withdrawn for analyses and detailed anamnesis was collected. All participants signed an informed 
consent for the management of personal anamnestic data and blood samples. The study was approved by the 
IRCCS MultiMedica ethical committee and conducted in accordance with the ethical principles deriving from 
the Declaration of Helsinki.
Genotyping. DNA samples were genotyped with Taqman assays for rs2070325 and rs11699009, to identify 
the haplotype. Data analysis was performed with QuantStudio software 1.1 (ThermoFisher Scientific).
Statistical analyses. SNP quality control allowed estimation of the minor allele frequency (MAF) and test-
ing for statistically significant deviations from the Hardy–Weinberg equilibrium. The most likely haplotype phases 
for each individual were estimated by the–hap command implemented in the PLINK software tool and confirmed 
by the Beagle v.4.1 software tool22, 23. The frequency of each haplotype allele was assessed by custom R scripts 
(www.r-project.org). As for SNP allele frequency, the haplotype allele frequency was estimated by counting the 
number of chromosomes carrying a specific haplotype divided by the total number of chromosomes observed.
Since systolic and diastolic blood pressure distributions deviated significantly from normal (Shapiro–Wilk 
test, p < 0.05), the non-parametric Wilcoxon rank-sum test was applied to evaluate the presence of statistically 
significant differences in terms of quantitative traits distribution between single SNP genotypes and between 
haplotype allele configurations (assuming a dominant or recessive genetic model). Multivariate linear regres-
sion with stepwise feature selection was employed to adjust the association statistics for the impact of demo-
graphical and clinical covariates (sex, age, diabetes, GTT, BMI, triglyceridemia, total and HDL cholesterolemia, 
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anti-hypertensive treatments) representing potential confounding factors. Treatment-specific associations were 
evaluated by including the SNP/haplotype x treatment interaction term in the linear regression fits.
The Wilcoxon rank-sum test or the Kruskal–Wallis test were applied to compare DBP and SBP distribution by 
categorical variable values as appropriate. The Spearman correlation test was applied to quantify the strength of 
the correlation between DBP, SBP, and continuous variables of interest. Statistical genetics analysis was performed 
with the R statistical software tool (www.r-project.org), except when specified otherwise.
Cloning and purification of recombinant BPIFB4-His protein. HEK293T cells were transfected with 
the WT-BPIFB4 or RV-BPIFB4 vector cloned in fusion with His-Tag. The recombinant protein was purified using 
affinity Nuvia IMAC Resin (Bio-Rad) under native conditions.
Evaluation of recombinant RV-BPIFB4 protein in human vessels. To translate the data obtained in 
the experimental model, we performed vascular reactivity studies using recombinant protein on superior thyroid 
artery (STA) removed from patients undergoing carotid revascularization24. Vascular reactivity was evaluated 
as previously described24. Vessels were incubated with increasing doses of protein (4.5, 9, and 18 ng/mL), and 
acetylcholine- or nitroglycerine-mediated vasorelaxation assessed. The experimental protocol was approved 
by IRCCS INM Neuromed ethical committee and carried out in accordance with the institute’s guidelines; all 
patients gave their informed consent for STA excision.
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